These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

4159 related items for PubMed ID: 23932901

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L.
    Orv Hetil; 2014 Jan 12; 155(2):62-8. PubMed ID: 24389322
    [Abstract] [Full Text] [Related]

  • 5. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR, Knight M.
    Clin Ther; 2015 Oct 01; 37(10):2153-79. PubMed ID: 26412799
    [Abstract] [Full Text] [Related]

  • 6. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Oct 01; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 7. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y, Shapiro MD.
    Endocr Pract; 2017 Jan 01; 23(1):100-112. PubMed ID: 27819772
    [Abstract] [Full Text] [Related]

  • 8. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L, Dani G.
    Orv Hetil; 2016 May 08; 157(19):746-52. PubMed ID: 27133274
    [Abstract] [Full Text] [Related]

  • 9. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M.
    Endocr Pract; 2017 Apr 08; 23(Suppl 2):1-87. PubMed ID: 28437620
    [Abstract] [Full Text] [Related]

  • 10. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, Wang CY, Chao TH, Liu PY, Su CH, Chien SC, Liou CW, Tang SC, Lee CC, Yu TY, Chen JW, Wu CC, Yeh HI, Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients.
    J Formos Med Assoc; 2017 Apr 08; 116(4):217-248. PubMed ID: 28242176
    [Abstract] [Full Text] [Related]

  • 11. Lipoprotein(a), cardiovascular disease, and contemporary management.
    Jacobson TA.
    Mayo Clin Proc; 2013 Nov 08; 88(11):1294-311. PubMed ID: 24182706
    [Abstract] [Full Text] [Related]

  • 12. The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.
    Hajhosseiny R, Sabir I, Khavandi K, Wierzbicki AS.
    Clin Pharmacol Ther; 2014 Jul 08; 96(1):64-73. PubMed ID: 24699033
    [Abstract] [Full Text] [Related]

  • 13. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA.
    Int J Clin Pract; 2011 Jan 08; 65(1):82-101. PubMed ID: 21105969
    [Abstract] [Full Text] [Related]

  • 14. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK.
    Atherosclerosis; 2015 Oct 08; 242(2):647-56. PubMed ID: 26296750
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2012 Oct 11; 11():125. PubMed ID: 23057687
    [Abstract] [Full Text] [Related]

  • 17. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
    Chapman MJ, Le Goff W, Guerin M, Kontush A.
    Eur Heart J; 2010 Jan 11; 31(2):149-64. PubMed ID: 19825813
    [Abstract] [Full Text] [Related]

  • 18. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun 11; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

  • 19. HDL-C: role as a risk modifier.
    Barter P.
    Atheroscler Suppl; 2011 Nov 11; 12(3):267-70. PubMed ID: 22152280
    [Abstract] [Full Text] [Related]

  • 20. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA.
    Atheroscler Suppl; 2005 Sep 11; 6(3):21-7. PubMed ID: 16054442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 208.